2024
Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.
Wu H, Sukhanova M, Tang H, Lu X, Zhong M, Deshpande H, Pollack S, Laskin W, Alexiev B. Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma. Archives Of Pathology & Laboratory Medicine 2024 PMID: 39164013, DOI: 10.5858/arpa.2024-0098-oa.Peer-Reviewed Original ResearchAtypical lipomatous tumor/well-differentiated liposarcomaMDM2-amplified liposarcomasDedifferentiated componentDedifferentiated liposarcomaAdverse eventsMitotic countLocal recurrence statusMDM2 copy numberAssociated with adverse eventsLog-rank testOverall tumor volumeUnivariate logistic regressionChromosome 12q13-15Statistically significant associationPercentage of cellsTumor dimensionTumor volumeTumor sizeMDM2 proto-oncogeneClinicopathological characteristicsPathology reportsGrade 3Recurrence statusUnivariate analysisMultivariate regression model
2022
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Morales C, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal Of Clinical Oncology 2022, 40: 2479-2490. PMID: 35394800, PMCID: PMC9467680, DOI: 10.1200/jco.21.01829.Peer-Reviewed Original ResearchConceptsProgression-free survivalDedifferentiated liposarcomaNext treatmentCommon treatment-emergent adverse eventsPatients age 12 yearsTreatment-emergent adverse eventsLonger progression-free survivalPlacebo-controlled studyPrimary end pointLines of therapyAge 12 yearsAdverse eventsOverall survivalPlacebo armSupportive careClinical benefitStudy treatmentPredictive biomarkersPreclinical modelsProspective validationGrade 3Dose reductionPlaceboSide effectsPatients